Failure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016
|
|
- Marsha Lane
- 6 years ago
- Views:
Transcription
1 Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16
2 Disclosures Board member for : Schering-Plough, Merck, Janssen, Gilead, Boehringer Ingelheim, BMS, Novartis, Roche, AbbVie, GSK, Vertex, Idenix Speaker for : Roche, Schering-Plough, Merck, Janssen, Gilead, BMS, Abbvie
3 Failure is a rare event in the DAAs era: Large real-world data confirm clinical trial results: GT-1 patients ( EASL 16) SIM/SOF SOF/LDV 3D SOF/DCV % 90% 80% 70% 60% 50% 40% 30% % 10% 0% 93% 93% 95% 94% 94% 93% 87% 88% 89% 98% 97% 96% 95% 94% 86% 94% 95% VA VA / HIV TRIO N Italian Portugese Spanish German Nb =2363/4104/ /8/ / 73 / / /1836/390/528 No impact of HIV HBV, diabetes and obesity on SVR Follow the EASL Guideline (93% vs 87%) Hypo Alb <35g/l negative predictor of SVR McCombs J et al: LBP-510,McGinnis J et al: LBP-514, Afdhal N et al: LBP-519, Aghemo A et al: LBP-500, Marinho T et al: LBP-523, Crespo, J et al: LBP-511, Calleja JL et al: LBP-512, Mauss. S et al: SAT-263
4 Failure is a rare event in DAAs era even in cirrhotic: Large real-world data confirm clinical trial results: Cirrhotic patients SAEs : 8.1% and 4 pts died from cirrhosis complication SVR rates(itt) : GT-1: 91%, GT-2: 80%, GT-3: 73%, GT-4: 83% Deterding K et al. EASL 16: SAT-194
5 What to do in case of failure? Resistance testing?
6 Role of Resistance Testing The presence of resistance associated variants to DAAs prior to treatment may have an impact on SVR, especially in pts with previous DAA treatment experience and/or cirrhosis Consider resistance testing prior to retreatment in patients who fail to achieve HCV cure with DAAbased treatments EASL 15 : recommendation on treatment of Hepatitis C. J Hepatol 15
7 Resistance issue RBV NS5B NUC High barrier to resistance NS5A.I I. NNuc NS5B NS5B NNI NS3/4 PI Modest barrier to resistance (esp to GT1a) Low barrier to resistance (esp to GT1a) NS5B NUC NS3/4 IP PI NS5A.I Very few or no RAS RASs with short half-life RASs with long half-life
8 Patients with RAVs (%) Long term follow-up of NS5A RAVs after Ledipasvir failure 73 patients included in ledipasvir containing regimen who failed to treatment 99% have NS5A RAVs at failure Long term follow-up ( up to 2 years after treatment discontinuation by ultra deep sequencing % 98 % % 95 % 86 % /58 42/43 45/45 52/55 50/58 Baseline FU 12w FU 24w FU 48w FU 96w NS5A RAVs persist in the majority of patients 2 years after treatment discontinuation EASL 15 - D après Dvory-Sobol H et al., abstr. O059, actualisé
9 SVR12 (%) 24 Wks of LDV/SOF After Failure of 8-12 Wks of LDV/SOF-Based Therapy in GT1 Pts Results from single arm of prospective phase II trial GT1 HCV infected pts previously treated with LDV/SOF 90/400 mg QD LDV/SOF-based therapy (N = 41) NS5B variants with resistance to SOF emerged during retreatment in 33% of pts (4/12) with virologic failure S282T: n = 3 (out of 12) Wks 60 n/n = 0 29/ 41 15/ 22 All No Yes Lawitz E, et al. EASL 15. Abstract O / 19 Cirrhosis 24/ 30 5/ 11 8 Wks 12 Wks Previous Tx Duration 11/ 11 No 18/ 30 Yes BL NS5A RAVs
10 Re-treatment of Patients who Failed an IFN-Free Regimen The re-treatment regimen should contain Sofosbuvir because of the high barrier to resistance 1 or 2 other DAA(s), if possible with no cross-resistance with the DAA(s) already administered Ribavirin Treatment duration should be 12 or 24 weeks (recommended in F3-F4) EASL 15 : recommendation on treatment of Hepatitis C. J Hepatol 15
11 German resistance network : Prevalence of RAS in DAAs failure according to genotype Genotype 1 (n = 195) 2 % 3 % Genotype 3 (n = 69) 1 % 5 % 6 % 10 % No RAS NS5A 2 % 4 % 19 % 41 % 14 % NS3 + NS5A NS5A + NS5B NS3 NS5B NS3 + NS5B 32 % 61 % No RAS NS5B NS5A + NS5B NS5A + NS5B NS3 + NS5A NS3 + NS5A + NS5B RAS in 90 % of patients RAS in 39 % of patients Vermehren J, et al. EASL 16, Abs. PS103.
12 SVR (%) % of RAS German resistance network : SMV/SOF failure 40 n = 27/49 (55 %) 18 % % No NS5A RAS alone 15 % No RAS NS3 NS5A NS5B NS5A + NS5B 4 % 4 % 7 % NS3 + NS5A NS3 + NS5B Retreatment with a regimen containing NS5A inhibitors LDV/SOF + RBV (n = 10) LDV/SOF + RBV (n = 13) PrOD + RBV (n = 3) PrOD + RBV (n = 1) Weeks Intermediate analysis: SVR 12 = 91 % (n = /22) 90 LDV/SOF + RBV PrOD + RBV 12 weeks. 24 weeks. 12 weeks. 24 weeks. Vermehren J. et al. EASL 16, Abs. PS103.
13 SVR (%) % of RASs German resistance network : LDV/SOF failure n = 11/90 (12 %) DCV/SOF failure n = 11/29 (38 %) % No NS3 RAS alone 77 % No RAS NS3 NS5A NS3 + NS5B Q80K considered as minor variant 5 % 9 % 5 % NS5A + NS5B NS3 + NS5A + NS5B Retreatment with a regimen containing a PI SMV/SOF + RBV (n = 6) 80 Intermediate analysis: SVR 12 = 86 % (n = 6/7) 75 SMV/SOF + RBV (n = 11) 60 PrOD + RBV (n = 4) 40 PrOD + RBV (n = 1) Weeks 0 SMV/SOF + RBV PrOD + RBV 12 weeks. 24 weeks. 12 weeks. 24 weeks. Vermehren J. et al. EASL 16, Abs. PS103.
14 % of RAS German resistance network : 80 NO SOF RAS PrOD Abbvie failure n = 5/27 (19 %) % % 40 % % % 0 No RAS NS5A NS3 + NS5B NS5A + NS5B NS3 + NS5A + NS5B Retreatment with a regimen containing a NS5B Nuc I. SOF + LDV + SMV + RBV (n = 1) SOF + LDV + RBV (n = 3) SOF + SMV + RBV (n = 1) weeks Vermehren J. et al. EASL 16, Abs. PS103.
15 SVR (%) % of RAS German resistance network : % No Y93H SOF/RBV failure n = 14/43 (42 %) % 0 No RAS NS5A (A30K/S) Retreatment with a regimen containing a NS5A. I. Intermediate analysis: SVR 12 = % (n = 7/7) 90 DCV/SOF + RBV (n = 3) DCV/SOF + RBV (n = 10) LDV/SOF + RBV (n = 1) Weeks 40 0 DCV/SOF + RBV LDV/SOF + RBV 12 weeks. 24 weeks. 12 weeks. 24 weeks. Vermehren J. et al. EASL 16, Abs. PS103.
16 Retreatment of HCV DAAs failure according to EASL guidelines First line regimen SOF/TVR +/- RBV SOF/TVR +/- RBV SOF/TVR +/- RBV SOF/PEG RBV SOF/PEG RBV SOF/SMV +/-RBV SOF/SMV +/-RBV SOF/DCV +/-RBV SOF/DCV +/-RBV SOF/DCV 32 patients, 66% F4 Genotypes repartition G4 25 % G3 19 % G1 9% G2 13 % G1B 22 % G1A 12 % All the patients were exposed to the NS5B inhibitor during the first line (Sofosbuvir) or ombitasvir. All the seconde line have used sofosbuvir baseregimen Each First line of treatment 12 weeks 24 weeks Secondline of treatment represents a single patient HCV Genotype G1 G1A G1B G2 G3 G4 SOF/PEG RBV SOF/LDV +/-RBV SOF/DCV +/-RBV SOF/DCV +/-RBV SOF/LDV +/-RBV SOF/DCV +/-RBV SOF/LDV +/-RBV SOF/DCV +/-RBV SOF/LDV +/-RBV SOF/DCV +/-RBV 32 retreated patients 11 during 12 weeks 21 during 24 weeks % SVR 12 (21/21) Second line regimen 12 patients under treatment or follow-up Laurain A et al EASL 16 :FRI- 8
17 Retreatment of HCV DAA failures: upon where no to go!! Eleven patients (mean age: 56.2 years, range: 48-64) infected with: -HCV genotype 1 (1a: n=4 ; 1b: n=3) -HCV genotype 2 (n=1) -HCV genotype 4 (n=2) -HCV genotype 6 (n=1) All patients had compensated liver disease (fibroscan: kpa) and failed to achieve SVR with previous all-oral regimen They had received SOF + DCV (n=6) ; DCV + SMV (n=1) ; SOF + SMV (n= 1) ; SOF + LDV (n=1) ; GRZ + EBV (n=1) ; Mericitabine + Danoprevir + ritonavir (n=1) ; without RBV for 12 weeks Geno type Baseline NS3 RAVs Baselin e NS5A RAVs M28A, Q30K Baseli ne NS5B RAVs Last ontreatment HCV RNA (UI/mL) SVR12 Failure NS3 RAVs Failure NS5A RAVs Failure NS5B RAVs 1a R155K, D168E None <12 (EOT) Relapse R155K, D168E M28A, Q30K None 1a R155K M28T None <12 (EOT) Relapse R155K Q30E None 1a R155K Q30K None <12 (Week R155K M28T, None 4) Q30K Relapse Discontin uation due to SAE* 1a None Q30K None <12 (EOT) Yes b None L28I, R30S None <12 (Week 6) Unknown Discontin uation due to SAE* RA Substitution (RASs) should be assess before retreatment HCV resistance was assessed at retreatment baseline by means of population sequencing of the NS3 protease, 1b None Y93H (S556 <12 (EOT) Yes NS5A and NS5B polymerase especially coding regions in those who have been treated previously G) Wk 12 Wk 24 Wk 36 SOF + DCV + SMV + RBV SVR12 with PI and NS5A I. 1b None None C316N <12 (EOT) Yes None None None <12 (EOT) Pending 4 D168E L28M, None <12 (EOT) Yes L30C 4 None L30S, None <12 (Week Pending Y93H 12) 6 Y56H, D168C None None <12 (EOT) Yes SAEs: Pulmonary arterial hypertension (n=1) ; Multi-organ failure possibly related to mitochondrial toxicity (n=1) - SOF+DCV+SMV+RBV for 24 weeks was associated with on-treatment response in all patients - However, One patient discontinued early due to SAE (possible mitochondrial toxicity) and virological outcome is pending - and at least 3 patients failed to achieve an SVR, one due to SAE (pulmonary arterial hypertension), the other two due to post-treatment relapse - Given the lack of other DAA class options, the latter patients should be considered incurable Hezode. C et al EASL poster THU-217
18 Just Around the Corner Sofosbuvir/velpatasvir
19 SOF/VEL + RBV 2 for 24 weeks : A good options for failure to NS5A inhibitors except in genotype 3 patients. SVR according to RAS and genotype G1 (n = 34) G2 (n = 13) G3 (n = 16) 82 % No RAS 28/34 18 % RAS 6/34 38 % No RAS 5/13 62 % RAS 8/13 19 % No RAS 3/16 81 % RAS 13/16 96 % SVR % SVR % SVR % SVR % SVR 77 % SVR 27/28 6/6 5/5 8/8 3/3 10/13 11/13 GT-3 patients G3 with Y93H mutations ; 9 (82 %) SVR 12 5 patients with 2 NS5A mutations; 5 SVR 12 3 patients with NS3 mutations; 3 SVR 12 Gane EJ. Et al. EASL 16, Abs. PS024
20 Market Authorization hypothesis SIM SOF/LDV SOF/VEL SOF/VEL/ GS-9857 ODV/AL33 5/SIM? SOF DCV ABT-493 /ABT-530 SOF/DC V VIEKIRAX Exvira Gra/Elb 2DAA Gra/ MK-3682 /MK DAA Pan genotypic activity
21 Treatment of patients who failed previous DAAs regimen SVR 12 SOF/ VEL/ GS weeks 1 relapse 127/128 63/63 21/21 34/35 9/9 All G1 G2 G3 G4, 6 Lawitz E. et al EASL 16, Abs. PS ABT-493 / ABT weeks in GT-1 patients ITT mitt Poordad F. et al. EASL 16, Abs. GS11
22 SOF/VEL/GS-9857 for 12 weeks in genotypes 1 to 6 patients with DAAs failure Impact of baseline RAS on SVR % Baseline RAS (77/128) % SVR % No RAS (51/128) % NS5A RAS only 15 % NS3 RAS only 99 % SVR 12 51/51 23 % multiple RAS 76/77 2 % NS5B RAS only Lawitz E. et al. EASL 16, Abs. PS008.
23 HCV RNA (log 10 UI/mL) SOF/VEL/GS-9857 for 12 weeks in genotypes 1 to 6 patients with DAAs failure Relapse : prior treatment and RASs evolution NS5A Y93H (> 99 %)* NS3 NS5B No RAS No RAS NS5A Y93H (> 99 %) NS3 Q80R (41 %) NS5B No RAS SOF + RBV 32 weeks. Peg-IFN 8 sem. SOF/VEL + GS weels. Follow up S8 58 yo GT-3 women with cirrhosis, HCV RNA 7,0 log 10 IU/ml Lawitz E. et al, EASL 16, Abs. PS008.
24 SOF/VEL/GS-9857 for 12 weeks : A good option in GT-1 DAAs failure Monocenter phase 2 trial in GT1 patients with DAAs failure : G1a (88 %), cirrhosis (50 %) Two arms study : SOF/VEL/GS-9857 (second generation PI) 12 weeks vs SOF/VEL/GS RBV 12 weeks. Previous treatment ( 6 weeks) SVR % 31 % 14 % % NS5A 41 % (/49) No NS5A 59 % (29/49) 16 % 12 % NS5A NS3 NS5B 24/24 24/25 SOF/VEL/GS weeks. SOF/VEL/GS RBV 12 weeks. Lawitz E. et al. EASL 16, Abs. PS021.
25 SOF/VEL/GS-9857 for 12 weeks : A good option in GT-1 DAAs failure HCV RNA (log10 UI/ml) Impact of RAS on SVR Resistance profil in the relapser NS5A % SVR 12 12/12 75 % baseline RAS (36/48) 25 % No RAS (12/48) 15 % NS5A RAS 29 % NS3 RAS 31 % Multiples RAS 97 % SVR 12 35/ LDV/SOF 24 weeks. M28V (1,7 %) Q30H (3,2 %) L31M > 99 %) 0 RAS 0 RAS SOF/VEL/GS RBV 12 weeks. M28T (> 99 %) Q30 L (2,4 %) Q30R (97,3 %) L31M (> 99 %) V36M (> 99 %) Q41R (> 99 %) D168G (96,4 %) D168S (2,4 %) 0 RAS FU-4 NS3 NS5B deep sequencing 61 yo African American male with cirrhosis and IL28B CC Lawitz E. et al. EASL 16, Abs. PS021.
26 ABT-493 and ABT-530 in GT-1 non cirrhotic DAAs failure patients Dose ABT-493 ABT-530 Dose RBV mg 1 mg ITT 300 mg 1 mg 800 mg SVR 12 Impact of baseline RAS on SVR mg 1 mg 0 mg 1 mg Modified ITT 300 mg 1 mg 800 mg 300 mg 1 mg Breakthrough Relapse Lost of FU SVR 12 15/16 (94 %) SVR 12 6/6 ( %) NS3 and NS5A RAS (n = 16) NO RAS (n = 6) NS3 RAS only (n = 15) NS5A RAS Only (n = 10) SVR 12 = % among patient with baseline NS5A Y93 mutation SVR 12 9/10 (90 %) SVR = % among patients with baseline NS3 Q80 or R155 mutations SVR 12 15/15 ( %) Poordad F. et al. EASL 16, Abs. GS11.
27 Conclusions In case of DAAs failure consider resistance testing prior retreatment. The re-treatment regimen should contain Sofosbuvir because of the high barrier to resistance 1 or 2 other DAA(s), if possible with no cross-resistance with the DAA(s) already administered Ribavirin Treatment duration should be 12 or 24 weeks (recommended in F3-F4) For those with multiple RASs against NS3 and NS5A, and advance disease, retreatment must be cautious with available drug and future treatment may be more promising
28 Thank you for your attention
HCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationA One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationIs HCV drug resistance an issue?
Is HCV drug resistance an issue? 5TH ASIAN CONFERENCE ON HEPATITIS&AIDS NANJING, CHINA 28-29 MAY 2016 FROM BASIC SCIENCE TO CLINICAL PRACTIC Jürgen Kurt Rockstroh Department of Medicine I, University Hospital
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationWhat do we need to know about RAVs clinically?
14 th European HIV & Hepatitis Workshop Rome, 25-27 May, 2016 What do we need to know about RAVs clinically? Stefan Zeuzem, MD University of Frankfurt Germany Background Resistance associated variants
More informationCases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More information10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationDavid L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
FORMATTED: 1/3/16 Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? Atlanta, Georgia: October 2, 216 David L. Wyles, MD Chief, Division of Infectious Disease Denver Health
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationHealth Without Barriers. HCV in prison Barriers to treatment, new Strategies and Outcomes
Health Without Barriers The European Federation for Prison Health HCV in prison Barriers to treatment, new Strategies and Outcomes Roberto Monarca HWBs President Vice President of the Italian Society for
More informationVirological tools for hepatitis C: re-treatment and resistance. Joop Arends Will Irving. by author
Virological tools for hepatitis C: re-treatment and resistance Joop Arends Will Irving Disclosures Joop Arends Advisory board: Gilead, Abbvie, Janssen, MSD, BMS (research) grants: Abbvie, BMS, MSD and
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationSofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4
Phase 3 Treatment Experienced Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Bourlière M, et al. N Engl J Med. 217;376:2134-46. POLARIS-4: Study Features POLARIS-4 Trial Design:
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationNS5A inhibitors: ideal candidates for combination?
NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang
More informationTreating HCV After Liver Transplantation: What are the Treatment Options?
4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationResistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Resistencias & Epidemiología Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic,
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationWhat Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationInterferon free therapy Are we getting there? Graham R Foster Queen Marys University of London
Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London IFN free therapy Disclosures I have received personal and institutional funding from companies that sell drug
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationHCV Treatment in 2016
HCV Treatment in 2016 Hugo E. Vargas, MD Professor of Medicine Mayo College of Medicine Medical Director, Clinical Trials Office Vice Chair, Department of Research Educational Goals Caveats: Cannot cover
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationIndividual Optmizaton of therapy. Graham R Foster Professor of Hepatology QMUL
Individual Optmizaton of therapy Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novarts, Springbank,
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationHepatitis C: Newest Treatment Options and What To Do When We Cure It!
Hepatitis C: Newest Treatment Options and What To Do When We Cure It! Richard Kalman, MD Division of Hepatology Department of Transplantation Einstein Medical Center Learning Objectives Scope of HCV How
More informationGenotype 4, finally cured? Imam Waked Professor of Medicine National Liver Institute
Genotype 4, finally cured? Imam Waked Professor of Medicine National Liver Institute Paris, January 12, 215 Disclosures Investigator, speaker, and advisory board member for: Roche, MSD, BMS, Gilead, Janssen,
More informationEASL and The Future of HCV Treatment
EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine
More informationC-CREST study, Part A: GZR + EBR or MK MK-3682 for genotypes 1, 2 and 3 - Phase II
Design 18 years Chronic HCV infection Genotype 1, 2 or 3 Treatment-naïve HCV RNA 1 IU/ml No cirrhosis * No HBV or HIV co-infection Randomisation Open-label * Liver biopsy or Fibroscan 12.5 kpa or Fibrotest
More informationHCV Update from AASLD 2016
HCV Update from AASLD 2016 Ahmed Elsharkawy Consultant Hepatologist QE Birmingham Secretary and Chair-Elect of BVHG BHIVA/BVHG Feedback Meeting November 2016 Speaker Name Ahmed Elsharkawy Statement Speaking
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationO. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki
O. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki Disclosures Advisory Board: Abbvie Pharmaceuticals Speaker: Gilead Sciences, Bristol-Myers Squibb Research
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationThe Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago
The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationHIV/Hepatitis C in France: data from real life cohorts LIONEL PIROTH CHU DIJON UNIVERSITY OF BURGUNDY DECEMBER LONDON
HIV/Hepatitis C in France: data from real life cohorts LIONEL PIROTH CHU DIJON UNIVERSITY OF BURGUNDY DECEMBER 2015 - LONDON The need Decreasing prevalence of chronic hepatitis C in French people living
More informationRapid Response from San Francisco: The Latest in the HCV Treatment Revolution
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationWhat s new in HCV/HIV coinfection therapy?
What s new in HCV/HIV coinfection therapy? Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases
More informationStudy Design - GT 1 Retreatment
Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks Eric Lawitz, Steven Flamm, Jenny C. Yang, Phillip S. Pang, Yanni Zhu, Evguenia
More informationDebate: Do We Need More HCV Drugs Con Standpoint
Debate: Do We Need More HCV Drugs Con Standpoint 18 th Antivirals PK Workshop, Friday 16 th June 2017, Chicago Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany Conflict
More informationTreatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy
Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy antonio.craxi@unipa.it Ad Board and grants: Abbvie, Achillion, BristolMyers Squibb,
More informationManagement of HCV in Decompensated Liver Disease
Management of HCV in Decompensated Liver Disease Michael P. Manns Hannover Medical School (MHH) Department of Gastroenterology, Hepatology and Endocrinology Helmholtz Center for Infection Research (HZI),
More informationWill difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
More informationHepatitis C - results in real life
Hepatitis C - results in real life Robert Flisiak Department of Infectious Diseases and Hepatology Medical University of Białystok, Poland 10th PHC Paris, 30-31 January 2017 Disclosures Advisor and/or
More informationHCV Treatment in 2016: is there still a role for IFNa and ribavirin?
HCV Treatment in 2016: is there still a role for IFNa and ribavirin? Heiner Wedemeyer Hannover Medical School Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie,
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More information